GLP-1 Prescription Guide: Evidence-Based Conversation Starters

Last reviewed: May 26, 2026

Last updated: May 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Getting a GLP-1 prescription starts with understanding your doctor's clinical framework: FDA-approved indications, BMI thresholds, comorbidity status, and medication history. GLP-1 receptor agonists are FDA-indicated for type 2 diabetes and chronic weight management in adults with obesity or overweight with weight-related conditions, making eligibility a medical conversation, not a lifestyle preference.

Many patients approach this discussion unprepared with metabolic context or family history relevant to peptide sensitivity. PlexusDx advocates for precision-guided conversations that include your baseline metabolic markers, genetic predispositions in GLP-1 and GIPR pathways, and how these factors align with your doctor's treatment algorithm—strengthening both your case and your provider's confidence in the recommendation.

Understand Your Doctor's Clinical Decision-Making Framework

Physicians evaluate GLP-1 eligibility using standardized criteria: BMI ≥30 kg/m² or ≥27 with weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea); prior weight loss attempts; absence of contraindications. Your doctor weighs these factors against medication safety profile and your medical history. Knowing this framework helps you prepare relevant data.

Come prepared with documented weight history, previous interventions (diet, exercise, prior medications), current metabolic labs (fasting glucose, HbA1c, lipid panel), and comorbidities. If you have type 2 diabetes, bring recent HbA1c trends. If weight-related, document blood pressure and family history of metabolic disease. This demonstrates informed, collaborative engagement with your provider's clinical process.

Key Clinical Markers That Strengthen Your GLP-1 Case

GLP-1 medications show strongest evidence in patients with elevated fasting glucose, insulin resistance markers, and metabolic syndrome. Request labs: fasting insulin, HOMA-IR (insulin resistance index), triglycerides, and HbA1c. These biomarkers provide clinical context beyond BMI alone and may align with your doctor's risk-benefit analysis for GLP-1 therapy.

Biomarker	Clinical Significance for GLP-1 Consideration
Fasting Glucose >100 mg/dL	Indicates prediabetes; GLP-1 improves glycemic control and may prevent type 2 onset
HOMA-IR >2.0	Reflects insulin resistance; GLP-1 enhances insulin sensitivity and metabolic function
Triglycerides >150 mg/dL	Associated with metabolic syndrome; GLP-1 reduces triglycerides and cardiovascular risk
HbA1c 5.7-6.4%	Prediabetic range; GLP-1 effective for weight loss and glycemic improvement in this population
BMI ≥30 or ≥27 with comorbidity	FDA eligibility threshold; combined with biomarkers, strengthens clinical justification for GLP-1

Building a Data-Driven Conversation With Your Provider

Prepare a one-page summary: age, BMI, weight history and prior interventions, relevant comorbidities, metabolic labs, family history of diabetes or obesity, and any previous medication trials. Avoid anecdotal claims; cite clinical trial outcomes instead. For example: 'GLP-1 medications reduced weight by 15-22% in clinical trials for patients with my BMI range and metabolic profile.'

Ask your doctor specific questions: Does my metabolic profile align with GLP-1 evidence? Are there contraindications I should know about? How would we monitor safety and efficacy? What side effect management strategies exist? Which formulation—oral or injection—fits my preference and compliance capacity? These questions position you as a collaborative partner in medical decision-making.

Safety, Eligibility Screening, and When GLP-1 May Not Be Appropriate

GLP-1 medications are contraindicated in personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pregnancy, severe gastrointestinal disease, or acute pancreatitis history. Your doctor must screen for these before prescribing. Be transparent about your full medical history, surgeries, and any prior adverse drug reactions. Honesty here protects your safety and strengthens your provider's confidence.

Even with ideal metabolic markers and BMI, GLP-1 may not be first-line if you have untreated eating disorders, severe kidney disease, or recent medication changes requiring stabilization. Some providers recommend lifestyle intervention first; others use GLP-1 as adjunct. Discuss your provider's treatment sequencing rationale. Understanding why they recommend a specific approach—or defer—demonstrates clinical reasoning you can respect and work within.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your predispositions in key peptide pathways—specifically variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—that relate to metabolic regulation and GLP-1 sensitivity. This information should be interpreted with a qualified healthcare provider as predisposition data, not as predictive of exact medication response or outcome.

Genetic predispositions in GLP-1 and GIPR pathways can support a more targeted discussion with your provider about why you may benefit from GLP-1 therapy over other weight-loss interventions. For instance, specific FTO variants are associated with higher baseline metabolic risk; GIPR variants may influence how you respond to dual GLP-1/GIP compounds like tirzepatide. This personalized context strengthens your clinical case without replacing medical evaluation.

Bringing your genetic predisposition report to your provider visit allows them to integrate this data into their clinical decision-making. Rather than guessing at medication fit, your doctor can discuss whether your genetic profile aligns with GLP-1 monotherapy, dual-agonist compounds, or alternative approaches—making your prescription conversation more precision-guided and informed.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.